Healthcare systems around the world are under mounting pressure. Ageing populations, the rising burden of chronic disease, and post-pandemic demand have pushed public health infrastructure to its limits.
According to the World Health Organization, musculoskeletal conditions alone affect more than two billion people globally, while mental health, cardiovascular disease, and access to primary care remain critical unresolved challenges in both developed and emerging markets.
The human cost of these failures is enormous; delayed diagnoses, overstretched clinicians, and millions of patients who simply cannot access the care they need. The question is no longer whether healthcare needs transformation; it is who will help fund it, and whether private capital can rise to meet that challenge.
This is where investment and social responsibility are beginning to converge in a compelling way.
Global investment in digital health and MedTech has accelerated sharply in recent years. The broader digital health market was valued at approximately $427 billion in 2025 and is projected to grow at a compound annual rate exceeding 21%. Within that, the AI-driven healthcare segment alone is expected to expand from $15.1 billion in 2022 to more than $187 billion by 2030, growing at roughly 37% per year.
Venture capital is increasingly recognising that technology-enabled healthcare, from AI diagnostics to digital therapeutics, represents both a structural growth opportunity and a genuine social good.
For too long, the worlds of impact-driven investing and return-driven investing were treated as mutually exclusive. That distinction is rapidly dissolving. Investors today are recognising that capital deployed into healthcare innovation does not simply generate financial returns; it extends lives, reduces suffering, eases the burden on overstretched public systems, and improves the quality of care for millions of people who would otherwise go without. The social multiplier of getting this right is profound.
Portugal has quietly emerged as one of Europe’s most interesting launchpads for this kind of innovation. The country offers a strong academic and life sciences talent base, competitive operating costs, and meaningful government support for technology-driven healthcare. The results speak for themselves.
One Portuguese digital therapeutics company, founded in 2015, has developed AI-powered digital physical therapy programmes for musculoskeletal conditions and has achieved a valuation of approximately $4 billion, becoming Portugal’s first health unicorn. Its technology has already helped hundreds of thousands of patients manage chronic pain and recover from injury without the need for costly in-person clinical intervention, reducing pressure on healthcare systems while delivering measurably better outcomes for patients.
Another has built an integrated suite of telehealth tools designed to empower patients and healthcare providers through personalised, digitally orchestrated care journeys, bringing quality healthcare to individuals regardless of their geography or socioeconomic circumstances. Both companies are emblematic of a broader movement; technology that does not simply digitise healthcare, but fundamentally reimagines how it is delivered and who it can reach.
These are not isolated success stories. They are evidence of a thriving ecosystem, one where innovation is driven not just by commercial ambition, but by a genuine desire to solve some of the most pressing health challenges of our time. For investors looking to align their capital with that mission, Portugal offers a uniquely compelling environment.
For international investors, Portugal has also long been attractive for another reason, the Golden Visa programme. Historically, much of that conversation centred on real estate. However, following reforms that removed the property investment route, the regulated investment fund pathway has become the primary mechanism for residency-by-investment.
The minimum investment for qualifying for the Portugal Golden Visa investment funds is €500,000, with funds regulated by the Portuguese Securities Market Commission (CMVM) and investing primarily in Portuguese companies. It is worth noting, however, that for the right investor, the residency benefit, whilst valuable, is increasingly the secondary consideration. The primary one is impact.
This shift has opened the door to something more purposeful.
RYSE’s recent joint venture with established Portuguese asset manager Fundbox, through the launch of the RYSE Golden Opportunities Fund, represents precisely this evolution.
Founded in 2017 and headquartered in London, RYSE is a venture capital firm focused on HealthTech and MedTech innovation, backing early-stage and growth-stage companies addressing global healthcare challenges, from digital diagnostics and therapeutics to medical devices and health AI. Their mandate is clear: identify and support the companies that will change how the world delivers care.
The fund is structured to meet the requirements of Portugal’s Golden Visa programme, offering investors legal residency through a regulated investment fund route. However, the proposition extends significantly beyond residency alone.
Every company within the RYSE portfolio is assessed not only on its commercial potential, but on its capacity to deliver meaningful clinical impact at scale, reducing hospital readmissions, improving early diagnosis rates, expanding access to specialist care, and driving down the systemic costs that are pushing public health budgets to breaking point.
Where previous generations of Golden Visa investors sought primarily to acquire property and residency rights, the RYSE Golden Opportunities Fund offers something fundamentally different; the opportunity to deploy capital into companies actively reducing pressure on healthcare systems globally, while also securing Portuguese residency and a longer-term pathway towards EU citizenship.
The residency is real and valuable, but it is the legacy of the investment that sets this proposition apart.
The investment thesis is grounded in real-world clinical impact. RYSE has previously partnered with NHS England through public-private initiatives aimed at identifying technologies capable of improving operational efficiency, reducing cost burdens, and expanding access to care in live healthcare environments.
The firm continues to work closely with major healthcare stakeholders, including global pharmaceutical companies such as Novartis, leading medical device manufacturers, including Medtronic, European and US insurers, and healthcare systems across the UK, GCC, and the United States.
These strategic relationships not only help validate the clinical relevance of portfolio companies but also help mitigate some of the risks traditionally associated with early-stage investing, providing routes to adoption that pure technology funds cannot access.
For high-net-worth investors seeking more from their capital than passive exposure to real estate, this represents a timely shift. The opportunity to secure Portuguese residency and EU access is significant. But the deeper opportunity, to be part of funding solutions to one of the defining challenges of our generation, is greater still.
Residency as a by-product of supporting the next generation of healthcare innovation is a fundamentally different proposition from what the Golden Visa conversation has historically offered. It aligns personal mobility strategy with measurable, lasting global impact.
As digital healthcare investment continues to attract increasing institutional attention worldwide, investors who move early into this space through vehicles such as the RYSE Golden Opportunities Fund may stand to benefit not only financially, but through the long-term legacy their capital helps create, a legacy measured not just in returns, but in lives improved, systems strengthened, and a healthier world built one investment at a time.
For further information on the RYSE Golden Opportunities Fund and Portugal Golden Visa eligibility, please contact Windsor Capital Management via our website.
